Completed PHASE2 INTERVENTIONAL 2-arm NCT01514370

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (CONTAIN)

ProspeCtive Study to Evaluate Efficacy, Safety and tOlerability of Dietary supplemeNT of Curcumin (BCM95) in Subjects With Active Relapsing MultIple Sclerosis Treated With subcutaNeous Interferon Beta 1a 44 mcg Three Times a Week (TIW)

Sponsor: Merck KGaA, Darmstadt, Germany

Conditions Multiple Sclerosis

Interventions Curcumin IFN beta 1a 44 mcg TIW Placebo

Updated 7 times since 2017 Last updated: Aug 20, 2018 Started: Apr 30, 2012 Primary completion: Mar 31, 2016 Completion: Mar 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Sclerosis and is currently completed. Merck KGaA, Darmstadt, Germany leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Feb 2019 — Jan 2021 [monthly]

Completed PHASE2
Jan 2019 — Feb 2019 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2019 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Data source: Merck KGaA, Darmstadt, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Naples, Italy